Cadralazine
Chemical compound
- C02DB04 (WHO)
- Ethoxy-N'-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}carbohydrazide
- 64241-34-5 Y
- 2515
- 2420 N
- 8T96I3U713
- ChEMBL2106561 N
- DTXSID4048725
- Interactive image
- O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1
InChI
- InChI=1S/C12H21N5O3/c1-4-17(8-9(3)18)11-7-6-10(13-15-11)14-16-12(19)20-5-2/h6-7,9,18H,4-5,8H2,1-3H3,(H,13,14)(H,16,19) N
- Key:QLTVVOATEHFXLT-UHFFFAOYSA-N N
Cadralazine is an antihypertensive of the hydrazinophthalazine chemical class.[1]
References
- ^ McTavish D, Young RA, Clissold SP (October 1990). "Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension". Drugs. 40 (4): 543–60. doi:10.2165/00003495-199040040-00005. PMID 2083513.
- v
- t
- e
Nonsympatholytic vasodilatory antihypertensives (C02)
- Hydralazine #
- Dihydralazine
- Endralazine
- Cadralazine
- Pildralazine
- see list
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e